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Purpose: Radiation therapy (RT) can increase the risk of cardiac events in patients with breast cancer (BC), but biomarkers
predicting risk for developing RT-induced cardiac disease are currently lacking. We report results from a prospective clinical
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trial evaluating early magnetic resonance imaging (MRI) and serum biomarker changes as predictors of cardiac injury and risk
of subsequent cardiac events after RT for left-sided disease.
Methods: Women with node-negative and node-positive (N-/+) left-sided BC were enrolled on 2 institutional review board
(IRB)−approved protocols at 2 institutions. MRI was conducted pretreatment (within 1 week of starting radiation), at the end
of treatment (last day of treatment §1 week), and 3 months after the last day of treatment (§2 weeks) to quantify left and right
ventricular volumes and function, myocardial fibrosis, and edema. Perfusion changes during regadenoson stress perfusion
were also assessed on a subset of patients (n = 28). Serum was collected at the same time points. Whole heart and cardiac substructures were contoured using CT and MRI. Models were constructed using baseline cardiac and clinical risk factors. Associations between MRI-measured changes and dose were evaluated.
Results: Among 51 women enrolled, mean heart dose ranged from 0.80 to 4.7 Gy and mean left ventricular (LV) dose from
1.1 to 8.2 Gy, with mean heart dose 2.0 Gy. T1 time, a marker of fibrosis, and right ventricular (RV) ejection fraction (EF) significantly changed with treatment; these were not dose dependent. T2 (marker of edema) and LV EF did not significantly
change. No risk factors were associated with baseline global perfusion. Prior receipt of doxorubicin was marginally associated
with decreased myocardial perfusion after RT (P = .059), and mean MHD was not associated with perfusion changes. A significant correlation between baseline IL-6 and mean heart dose (MHD) at the end of RT (r 0.44, P = .007) and a strong trend
between troponin I and MHD at 3 months post-treatment (r 0.33, P = .07) were observed. No other significant correlations
were identified.
Conclusions: In this prospective study of women with left-sided breast cancer treated with contemporary treatment planning,
cardiac radiation doses were very low relative to historical doses reported by Darby et al. Although we observed significant
changes in T1 and RV EF shortly after RT, these changes were not correlated with whole heart or substructure doses. Serum
biomarker analysis of cardiac injury demonstrates an interesting trend between markers and MHD that warrants further investigation. Published by Elsevier Inc.

Introduction
Based on multiple randomized trials and the subsequent
Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) meta-analysis, significantly reduced rates of
locoregional recurrence with adjuvant radiation occur after
breast-conserving surgery and survival is significantly
improved.1 As more effective screening, surgical techniques, and systemic therapies are developed, there is
increased interest in balancing the need for radiation treatment with its potential acute and late side effects. Although
in women with breast cancer with regional nodal involvement, the addition of regional nodal radiation has been
shown to improve disease-free survival and breast cancer
−specific survival, this improved disease control comes at
the cost of increasing dose to the heart, lung, and draining
lymphatics.2,3 Regional radiation therapy (RT) has been
shown to increase rates of lymphedema and pneumonitis.2,3
Similarly, radiation’s late effects on the heart have been
well documented in several retrospective cohort and observational trials,4-10 but prospective evidence quantifying the
damage and informing our understanding of its mechanisms
remains lacking. From long-term follow-up of patients with
lymphoma, it is known that radiation therapy can lead to an
increased risk of myocardial infarction, valvular dysfunction, systolic and diastolic function abnormalities, and heart
failure among cancer survivors.11,12 Patients with breast
cancer receive lower doses to smaller volumes of the heart
compared with lymphoma patients, but with their excellent
long-term survival, it is crucial to understand the potential
effects of low-dose radiation therapy.

Although cardiac injury after breast radiation therapy
remains a significant concern, there is a paucity of validated
biomarkers of cardiac injury that either identify women at
risk for cardiac injury or who have experienced clinically
meaningful damage. Efforts to minimize heart dose delivered
during breast radiation therapy have centered around several
planning and treatment delivery techniques. These include
patient positioning techniques such as treatment in the prone
position; treatment planning techniques such as cardiac
blocking, partial breast radiation, or intensity modulation;
and treatment machine techniques that include respiratory
gating, deep inspiration breath hold, and use of intraoperative
electron radiation or protons instead of photons,13,14 although
some of these technologies are not yet widely available.
Although effective, these strategies can still result in doses of
radiation to be delivered to the heart with the potential for
long-term negative effects. An increased understanding of
cardiac injury susceptibility and need for these techniques
represents an unfilled clinical need.
Cardiac MRI can be implemented to evaluate cardiac
dysfunction including alterations in chamber structure and
function, myocardial perfusion, and tissue properties using
T1 and T2 mapping.15,16 For detection of coronary artery
disease, MRI outperforms single-photon emission computed tomography (SPECT) dobutamine stress echocardiography for the detection of ischemia, and features such as
left-ventricular ejection fraction and inducible perfusion
defects are predictive of major adverse cardiovascular
events.17-20 MRI also can detect wall-motion abnormalities,
valvular dysfunction, inflammation, and myocardial fibrosis
and edema.21 Dynamic contrast-enhanced MRI (DCE-
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MRI) during stress and rest can evaluate the combined
effects of both microvascular and epicardial coronary artery
disease.22 Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiation
therapy and may potentially identify patients for aggressive
intervention to prevent future cardiac events.
At present, various data exist on potential biomarkers of
cardiac radiation exposure and damage, and these have not
always been systematically assessed in a longitudinal fashion in patients undergoing breast radiotherapy.23-28 The
potential use of imaging and blood-based biomarkers suggests that additional study in this area is warranted. Potential biomarker candidates have been identified based on
other processes affecting heart function in a way similar to
probable mechanisms of RT-related injury and may be of
use as indicators of early cardiac injury in women undergoing breast radiation therapy. For fibrosis and left ventricular
dysfunction, these include galectin-3 and NT-Pro brain
natriuretic peptide.29,30 Other possibilities include for myocyte destruction, troponin, and for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and
growth differentiation factor.31
To determine whether blood-based or imaging biomarkers
are viable for the detection of early cardiac injury, we
designed a prospective, single-arm, multi-institutional observational clinical study to assess early imaging with MRI and
blood-based biomarkers of cardiac injury. We hypothesized
that imaging and blood biomarkers of cardiac exposure
might be used as a first step to identify patients at increased
risk for cardiac effects. These patients could then be targeted
for close monitoring and early intervention, potentially with
medications such as statins or angiotensin-converting
enzyme (ACE) inhibitors. Additionally, by characterizing a
time-course and radiation dose-volume relationship, potentially real-time modifications might be made to RT field
design for patients sensitive to RT effects. Identifying candidates could also enable prioritization of cardiac-sparing treatment planning and delivery techniques for future patients.

Materials and Methods
Clinical study
Two institutional review board (IRB)−approved protocols
for single-arm clinical studies were developed to identify
blood and imaging biomarker changes with cardiac

Pre-RT MRI
and blood
draw
Within one week
of RT start

Fig. 1.
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exposure to radiation. The trial was registered with the
National Institutes of Health national trials registry at clinicaltrials.gov with the trial IDs of NCT02494453 and
NCT02496260. Patients who were to receive RT for leftsided breast cancer and who could undergo contrastenhanced MRIs were eligible. Patients were recruited at
both institutions between July 2015 and March 2018, and
56 patients were accrued with 5 screening ineligible.
Figure 1 summarizes the study timeline with all evaluated
patients undergoing 3 MRIs (before RT, immediately postRT, and 3 months post-RT) and blood draws at corresponding timepoints.

Radiation therapy
Conventional dose and fractionation was used for all
patients (1.8-2.0 Gy/fraction) with total dose to 50 Gy with
an optional boost allowed to 60 Gy in 2 Gy/fraction. No
matched electron fields were allowed. All treatment was
delivered with 3D conformal treatment planning (3DCRT)
or intensity modulated radiation therapy (IMRT). Only photons were used for treatment with no use of protons.

MRI
Serial ECG-gated steady-state free precession MRI with a
body coil was performed to quantify left and right ventricular volumes and function, precontrast quantitative T1- and
T2-mapping to myocardial fibrosis and edema, and regadenoson stress perfusion. Motion correction for T1, T2, and
dynamic perfusion imaging was performed inline during
image reconstruction.32 Baseline MRI was performed after
the completion of all chemotherapy. MRI imaging was performed using a standardized protocol on a designated Siemens 3T wide bore MRI scanner (Siemens Skyra, Siemens
Medical Imaging, Erlangen, Germany) or a Philips 3T (Philips Ingenia, Philips Medical Systems, Cleveland, OH)
wide bore MRI scanner. After image localization, ECGgated steady-state free precession images were obtained in
short-axis, 2-chamber, 3-chamber, and 4-chamber views.
T1 and T2 mapping were performed before the administration of contrast. Dynamic contrast enhancement imaging
was performed during infusion of gadopentetate dimeglumine at rest and for a subset of patients imaged on the Siemens scanner, during regadenoson stress (0.4 mg). A dose
of 75 mg of aminophylline was administered intravenously

Standard of care RT

End of RT
MRI and
blood draw

3 months
post-RT MRI
and blood draw

On last day
of RT

Overview of the clinical study. Abbreviations: MRI = magnetic resonance imaging; RT = radiation therapy.
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after completion of stress perfusion imaging to reverse the
effects of regadenoson. Axial phase contrast imaging at the
level of the left pulmonary artery and double oblique longaxis steady-state free precession imaging of the aorta were
performed for quantification of aortic pulse wave velocity.
LV and RV volumes and ejection fraction were quantified
by manually tracing motion corrected end-diastolic and
end-systolic frames on short-axis images. T1 and T2 were
quantified on motion-corrected short-axis images acquired
at the basal, midventricular, and apical levels of the left
ventricle. Circumferential strain was quantified from ECGgated short-axis images using speckle tracking.33 Strain
was quantified across all short-axis steady-state free precession slices and regional values computed globally and for
regions of the left ventricle based on standard segmentation.
Perfusion imaging was performed on 3 short-axis slices
covering the base, mid, and apical left ventricle. Myocardial
perfusion reserve index (MPRI) was computed globally and
for regions of the left ventricle using standard segmentation. All MRI quantification was performed using a standard commercial digital imaging software tool for cardiac
MRI (CMR42, Circle Cardiovascular Imaging, Calgary,
Canada). Owing to known challenges with combining multivendor quantitative data, serial images were normalized
such that subjects served as their own controls and the study
site (ie, MRI vendor) was considered in subsequent analysis. MRI parameters assessed included myocardial precontrast T1, myocardial T2, left ventricular end-diastolic
volume, left ventricular end-systolic volume, left ventricular ejection fraction, left ventricular mass, right ventricular
end-diastolic volume, right ventricular end-systolic volume,
right ventricular ejection fraction, myocardial perfusion
reserve index (global), myocardial perfusion reserve index
(anterior), left ventricular circumferential strain, quantitative T1 and T2 mapping, aortic pulse wave velocity, and, in
a subset, stress myocardial perfusion reserve
(Supplemental Fig. E1).

Blood biomarkers
The following serum markers (high-sensitivity cardiac troponin I [cTnI; Singulex Erenna Immunoassay], endothelin
1 [ET-1; Singulex ELISA], interleukin 6 [IL-6; Singulex
ELISA], high-sensitivity C-reactive protein [hsCRP; Singulex ELISA], cholesterol, high-density lipoprotein [HDL],
low-density lipoprotein [LDL], triglycerides [Trig], and Nterminal pro B-type natriuretic peptide [NT pro-BNP; Singulex ELISA]) were collected for evaluation. Blood samples were collected at the same time points (pretreatment
baseline, end of radiation treatment, and 3 months postradiation treatment) for all patients.

Heart dose and contouring
The whole heart and cardiac substructures were contoured
on the CT scan using a coregistered cardiac MR to

International Journal of Radiation Oncology  Biology  Physics

supplement the information. Guidance of heart contouring
was added by published heart atlases as well as the RTOG
Atlas for Organs at Risk for Thoracic RT.34,35 All contours
were reviewed by radiation oncology attendings and edited
for consistency. Cardiac substructures were contoured using
MRI registered to CT scans and dose to the whole heart and
cardiac
substructures
was
calculated
(Supplemental Fig. E2). For each patient, a rigid registration was performed for the T2 MR data sets to the CT simulation data set to enable contouring of substructures. The
initial registration focused on the boundaries between the
heart and other tissues. Then, the registration was biased
toward the left ventricle region to account for proximity to
the dose distribution and the regions of interest for the dosimetric evaluation. This methodology is consistent with that
in American Association of Physicists in Medicine Task
Group 132.36 Scan segmentation was performed initially by
a single trained radiation therapist with all tracings individually reviewed and adjusted by a single core cardiovascular
training statement level 3−trained cardiologist with 13 years
of cardiac MRI experience. All processing was consistent
with Society for Cardiovascular Magnetic Resonance recommendations.37 The following dose metrics were
extracted and evaluated: whole heart maximum, mean, V50
Gy, V30 Gy, and V5 Gy, and total left ventricle (LV), anterior LV, inferior LV, lateral LV, and septal LV were
extracted and evaluated for associations with MRI endpoints.

Statistical analysis
Univariable regression models were fit to assess for correlation of baseline clinical factors and baseline imaging biomarkers. Longitudinal regression models were fit to test
whether mean values of imaging biomarkers changed from
baseline to end of treatment or 3-month timepoint. The
impact of RT heart dose on change from baseline in imaging biomarkers was assessed using longitudinal regression
models including patient level random intercepts to account
for within patient between time correlation. These models
also adjusted for doxorubicin by including it as a covariate.
Associations between blood biomarkers and radiation dose
were assessed using Pearson correlation coefficients with
separate estimates obtained at each timepoint (baseline,
post-treatment, or 3-month). The P values shown in tables
are nominal P values, but the Benjamini-Hochberg method
was implemented to address multiple testing between biomarkers and mean heart dose to control the false discovery
rate (FDR) at 0.10. No FDR correction was used when
assessing correlation among biomarkers. No imputation
was performed for missing data. Statistical significance was
defined as a 2-sided P value <.05, although given the early
stage of this research, we also note potentially interesting
findings with P values <.10. All analysis was performed
using the R statistical package.
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Table 1 Demographics of the patients included in the trials
(N = 51 patients)
Patient characteristics

Mean (range)

Age
Body mass index

56.8 (28-74)
32.0 (20.3-48.7)
Number (percentage)
4/51 (8%)
24/51 (47%)
17/51 (33%)
13/51 (25%)
24/51 (47%)
26/51 (51%)
1/51 (2%)

Underlying coronary artery disease
Underlying cardiac risk factors*
Smoking (current)
History of adriamycin
African American
Caucasian
Asian

5

associations between clinical factors and MRI changes
(Supplemental Table E2). Additional analysis in which
patient and clinical characteristics of age, cardiac risk,
underlying CAD, smoking status, BMI, use of doxorubicin,
and treatment site were modeled for associations with baseline measures of T1, right ventricular ejection fraction
(RVEF), global myocardial perfusion reserve index
(MPRI), or MPRI on the anterior wall also demonstrated no
significant associations, although there was a trend for baseline MPRI anterior wall measurements (P = .07) with BMI
that might become significant in a larger study.

*

Underlying cardiac risk factors (hypertension, hyperlipidemia, or
type 2 diabetes).

MRI changes after treatment

Results
Patient characteristics
Between and June 2015 and July 2017, 51 women with leftsided breast cancer from 2 institutions were enrolled with
clinical and relevant cardiac-related demographic information summarized in Table 1. As anthracycline receipt was
part of the chemotherapy regimen for almost all women
receiving chemotherapy (12/13 women), anthracycline
receipt was listed as representative in the table. Similarly,
as only 1 woman received anti-HER2 therapy, this is not
included in the table. As part of the study, pretreatment
blood draws and MRI before the initiation of treatment
were performed, as well as immediately at the end of the
radiation therapy course of treatment and again 3 months
after treatment completion (Fig. 1).

Heart dose
In this cohort, the mean heart dose (MHD) for all patients
was 2.0 Gy with a range of 0.80 to 4.69 Gy
(Supplemental Fig. E3). The mean LV dose was 3.0 Gy
with a range of LV 1.10 to 8.2 Gy (Supplemental Table
E1). The average whole heart maximum dose (to 0.1 cm3)
ranged from 7.2 to 58.6 Gy with an average maximum dose
of 29.8 Gy. Additional heart dose metrics used in the analysis (V50, V30, V5, and anterior, inferior, lateral, and septal
LV doses) are shown in Supplemental Table E1.

Clinical factors and influence on MRI features at
baseline
The analysis of associations among baseline clinical factors
(age, underlying coronary artery disease [CAD], cardiac
risk, smoking, body mass index [BMI], and doxorubicin)
and MRI metrics performed at baseline, end of treatment,
and 3 months post-treatment did not reveal any significant

Example MRI parameters assessed included left and right
ventricular volumes and ejection fractions, left ventricular
circumferential strain, quantitative T1 and T2 mapping,
aortic pulse wave velocity, and, in a subset of patients,
stress myocardial perfusion reserve as shown in
Supplemental Figure E1. On average a decrease in the T1
measure post-treatment compared with baseline was
observed at both post-treatment scan time points (immediately at the end of treatment, −20, P = .022 and at 3 months,
−23, P < .001). A decrease in the apical T1 signal at both
the end of treatment (−22.29, P = .008) and the 3-month
time point (−16.09, P = .04) was also observed. In addition,
a significant decrease in RVEF was seen at the end of treatment (−4.63, P = .003); it was, however, no longer significant at the 3-month time point (−1.02, P = .35). On
average, all other MRI endpoints (T2, LVEF, MPRI, and
MPRI anterior wall) did not significantly change between
baseline and post-treatment (Supplemental Table E3).
Associations among dose and age, CAD, cardiac risk,
smoking, BMI, and doxorubicin receipt (strong trend in the
baseline modeling) were then evaluated with changes in
MRI measurements (T1, RVEF, MPRI, and MPRI anterior
wall) (Supplemental Table E4). In this case, dose was considered either to the whole heart (as measured by mean
heart dose) or to the left ventricle (as measured by mean
dose to the left ventricle). Across all models there was no
significant dose effect seen with any of the MRI measurements. This was true for dose defined as either mean dose
to the entire heart or dose to the left ventricle. This was also
true when considering whole heart maximum, mean, V50
Gy, V30 Gy, and V5 Gy, and total LV, anterior LV, inferior
LV, lateral LV, and septal LV doses as there were no associations with MRI changes. The only variable that showed
a strong trend with the MRI measurements across these
MRI measurements was receipt of doxorubicin with outcome of change in MPRI (decreased perfusion, P = .06).
Mean heart dose and mean left ventricle doses had no significant dose effect seen with any of the MRI measurements
across all models tested (Supplemental Table E4).
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Table 2

Baseline biomarkers

cTnI, pg/mL
ET-1, pg/mL
IL-6, pg/mL
hsCRP, mg/L
CHOL, mg/dL
HDL mg/dL
TRIG, mg/dL
NT pro-BNP, pg/mL
LDL, mg/dL

n

Mean

SD

Median

Minimum

Maximum

41
41
41
38
38
38
38
38
38

3.13
2.39
2.66
4.42
200.26
51.26
136.53
98.38
124.55

4.57
0.95
2.37
3.97
52.42
17.72
71.85
112.86
49.41

1.00
2.10
1.90
3.06
196.50
51.00
121.00
63.70
119.00

0.20
1.40
0.20
0.15
73.00
24.00
60.00
8.13
27.00

18.10
5.20
10.80
14.90
395.00
91.00
414.00
539.50
315.00

Biomarkers below the lower limit of detection (LLD) are included as LLD/2.
Abbreviations: CHOL = cholesterol; cTnI = cardiac troponin I; ET-1 = endothelin 1; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; LDL = low-density lipoprotein; NT pro-BNP = N-terminal pro B-type natriuretic peptide; TRIG = triglycerides.

Blood biomarkers of cardiac injury
Table 3 Pearson correlation coefficients r for baseline
biomarkers
Biomarker 1

Biomarker 2

CHOL, mg/dL
ET-1, pg/mL
ET-1, pg/mL
ET-1, pg/mL
HDL, mg/dL
hsCRP, mg/L
IL-6, pg/mL
IL-6, pg/mL
IL-6, pg/mL

LDL, mg/dL
hsCRP, mg/L
NT pro-BNP, pg/mL
TRIG, mg/dL
TRIG, mg/dL
HDL, mg/dL
HDL, mg/dL
hsCRP, mg/L
NT pro-BNP, pg/mL

r
0.95
0.41
0.42
0.44
−0.49
−0.50
−0.32
0.45
0.45

P value
<.001
.011
.008
.005
.002
.001
.048
.005
.004

Abbreviations: CHOL = cholesterol; ET-1 = endothelin 1;
HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive
protein; IL-6 = interleukin-6; LDL = low-density lipoprotein; NT proBNP = N-terminal pro B-type natriuretic peptide; TRIG =
triglycerides.
Only pairs with significant correlation (P < .05) are shown.

Table 4 Pearson correlation coefficients r between biomarkers (post-treatment absolute value) and mean heart dose
Biomarker

Mean heart dose

r

CHOL, mg/dL
cTnI, pg/mL
ET-1, pg/mL
HDL, mg/dL
hsCRP, mg/L
IL-6, pg/mL
LDL, mg/dL
NT pro-BNP, pg/mL
TRIG, mg/dL

Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose

−0.18
0.27
0.17
−0.10
−0.02
0.44
−0.22
0.26
0.11

Table 2 presents baseline levels of cTnl, ET-1, IL-6,
hsCRP, cholesterol, HDL, LDL, Trig, and NT pro-BNP.
There was a significant correlation among baseline levels of
several of the biomarkers including cholesterol and LDL,
ET-1, and hsCRP, NT pro-BNP and triglycerides, HDL and
triglycerides, hsCRP and HDL, and IL-6 and HDL, hsCRP,
and NT pro-BNP, as noted in Table 3. This significance persisted for multiple biomarkers at the end of treatment and at
the 3-month post-treatment time points (Supplemental
Tables E5, E6). At the completion of treatment, a significant positive correlation existed between MHD and IL-6
levels (r 0.44, P = .007) but not with any of the other
serum-based markers (Table 4). Of note, this correlation
between MHD and IL-6 levels was not maintained at the 3month time point. Likewise, at 3 months post-treatment, a
strong trend existed between mean heart dose and cardiac
troponin I (cTnI) (r 0.33, P = .07) but none of the other
serum markers (Table 5). There was a strong, although not
significant, positive trend between mean heart dose and
Table 5 Pearson correlation coefficients r between biomarkers (3-month absolute value) and mean heart dose

P value

Biomarker

Mean heart dose

r

.285
.106
.310
.548
.889
.007*
.196
.122
.515

CHOL, mg/dL
cTnI, pg/mL
ET-1, pg/mL
HDL, mg/dL
hsCRP, mg/L
IL-6, pg/mL
LDL, mg/dL
NT pro-BNP, pg/mL
TRIG, mg/dL

Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose
Mean heart dose

0.23
0.33
−0.29
0.27
−0.02
−0.04
0.20
−0.07
−0.20

Abbreviations: CHOL = cholesterol; cTnI = cardiac troponin I; ET1 = endothelin 1; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; LDL = low-density lipoprotein; NT pro-BNP = N-terminal pro B-type natriuretic peptide;
TRIG = triglycerides.
Boldface indicates P value < .05
*
Indicates significance at a false discovery rate = 0.10.

P value
.251
.073*
.110
.166
.923
.835
.320
.734
.322

Abbreviations: CHOL = cholesterol; cTnI = cardiac troponin I; ET1 = endothelin 1; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; LDL = low-density lipoprotein; NT pro-BNP = N-terminal pro B-type natriuretic peptide;
TRIG = triglycerides.
Boldface indicates P value < .05
*
Indicates significance at a false discovery rate = 0.10.
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markers of cardiac injury at the end of radiation treatment,
specifically cTnI and NT pro-BNP (Table 4). Similarly, at 3
months postradiation, there was an inverse correlation
between mean heart dose and ET-1, in addition to the strong
trend toward positive correlation of MHD and cTnI at that
time point (Table 5). Correlation matrices and scatter plots
for biomarkers at baseline, at 3 months, and the change
between them are included in Supplemental Figures E4 to
E6.

Discussion
In this prospective multi-institutional study of 51 patients
with left-sided breast cancer undergoing radiation therapy,
we found that heart doses were very low relative to historical doses reported by Darby et al, with a mean heart dose of
2.0 Gy. Assessment of early MRI changes after radiation
therapy demonstrated that T1 time, a marker of fibrosis,
shortened significantly and RV ejection fraction decreased
significantly after treatment, but these changes were not
dose dependent. T2 mapping, a marker of edema, and
LVEF did not significantly change. No risk factors were
associated with baseline global perfusion, although lower
baseline anterior perfusion trended with higher baseline
BMI (P = .07). Additionally, prior receipt of doxorubicin
was borderline significantly associated with changes in cardiac perfusion after RT (decreased perfusion, P = .06), and
MHD was not associated with perfusion changes. IL-6 levels significantly increased as a function of MHD immediately at the end of treatment, and there was a persistent
positive correlation that trended toward significance for cardiac troponin I both at the end of treatment and at the 3month time point. These data suggest that modern conventional MRI analysis tools and serum biomarkers may not be
sufficiently sensitive to identify significant changes to the
heart or circulating biomarkers and suggest that such injury
may not occur with these low doses of radiation during the
timeframe studied, though long-term cardiac outcomes are
not yet available from this cohort.
This study builds on an extensive body of literature evaluating various imaging techniques to detect cardiac injury
after breast radiation. Heggemann et al recently reported
largely similar findings in a 49-patient prospective cohort
study in which patients treated with 3-dimensional conformal radiation therapy (3DCRT) or IMRT showed transient
decreases in EF with reduction in mitral and tricuspid annular plane systolic excursion, though this reduction was still
within the normal range.38 The authors concluded that at
least within 24 months of breast radiation therapy, only subclinical cardiac changes were observed in patients treated
with 3DCRT or IMRT. Likewise, Bergom et al recently
noted that in 20 patients with node-positive breast cancer
treated with anthracycline-based chemotherapy and
3DCRT, cardiac magnetic resonance (CMR) had no clinically abnormal CMR findings at a median follow-up time
of 8.3 years.39 Finally, Clasen et al recently found in a
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prospective longitudinal study of 86 patients with breast
cancer treated with photon or proton radiation therapy that
there are modest subclinical changes in measures of cardiac
function in the short-term (LVEF and longitudinal strain)
with no changes in circumferential strain or diastolic function.40 In keeping with the results presented here, these and
other studies suggest that current conventional imagingbased approaches may not be sensitive enough to detect
clinically relevant cardiac dysfunction when cardiac radiation doses are kept low with modern treatment planning.
Interestingly, there was a trend between cardiac troponin
1 at end of treatment and at 3 months’ post-treatment with
the mean heart dose, although this did not reach statistical
significance. This possibly suggests that myocardial injury
may be occurring even in range of the very low heart doses
in this study. A statistically significant relationship was
noted between mean heart dose and IL-6, a marker of acute
inflammation. This cytokine has complex effects in chronic
and acute exposures that range from protective to proatherogenic.41 These significant correlations even in a small
number of patients with low doses of radiation to the heart
in the present study suggest that further evaluation of these
markers is warranted. IL-6 is a marker of inflammation that
can be elevated in a variety of cardiac conditions including
after radiation treatment.42,43 The role of IL-6 and possibly
troponin I elevation warrants further investigation and if
validated in additional studies, they may be of interest as
biomarkers of cardiac injury after radiation. This may have
clinically meaningful implications and could be part of a
risk-stratified approach to patient monitoring after radiation. These biomarkers may identify the patients most at
risk for effects to the heart and may also identify those
patients most likely to benefit from more aggressive cardiac
monitoring in the months and years after the completion of
radiation therapy. If they begin to increase even during the
course of radiation therapy administration, they might also
be incorporated into personalized radiation treatment planning and dose adjustments; these would be worthy avenues
of further research.
In addition to seeing no dose effect based on mean heart
dose in this study, no significant effect was observed of
dose to any of the cardiac substructures on the MRI or
blood-based biomarkers we evaluated. Indeed, evidence for
substructure importance for cardiac injury remains hypothesized but unconfirmed. There is some evidence that dose to
subsegments of the left ventricle and coronary artery have
been associated with more frequent cardiac injury, albeit
with doses to these substructures that were much higher
than seen in our study.44-46 Accurate and consistent delineation of cardiac substructures remains a challenge and may
explain this lack of significance, although cardiac MRI
information improves the ability to accurately contour these
substructures and was used in this study.47 Perhaps more
likely, the very low doses delivered to the heart seen in this
study may indeed be below the threshold required to demonstrate changes on MRI, even using modern sequences
and approaches.
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A number of limitations need to be considered when
interpreting the conclusions of this study. Foremost among
them is the limited sample size included. Although significant associations were noted even in this small cohort, several MRI and biomarker parameters showed a trend toward
significance that perhaps would be more readily discerned
in a larger cohort of patients. This limited patient number
constrains the ability to detect smaller yet still clinically relevant changes that may be detected by cardiac MRI or
serum-based biomarkers as has been reported by other
groups. Referral bias is also a concern as patients had to
consent to be part of the study, and thus may not be a true
representation of the entire population. Most of the cohort
were Caucasian or African American women, with little
representation of Asian or Hispanic populations. Also, the
very low mean heart doses suggest that in an era of modern
radiation treatment planning in which MHD is strictly limited during treatment planning, heart dose from breast radiation can be effectively minimized, and thus may mitigate
negative cardiac effects that would have been seen in
patients treated more than 5 to 10 years ago. Finally, there
was limited follow-up in this study (3 months), and it is
unclear whether negative cardiac effects of radiation would
become more apparent with longer follow-up, an issue that
will need to be addressed in subsequent studies.
Because cardiac toxicity constitutes a meaningful late
effect for patients who receive radiation therapy for breast
cancer, clinical decision-making at the time of treatment is
complex. Tradeoffs must be made with inadequate information, including the extent to which to prioritize the dosimetric coverage of treatment targets to ensure tumor control
versus limiting the dose that may be received by the heart.
Studies such as the one by Darby et al suggest cardiac toxicity might occur even with low doses of radiation, basing
their modeling of the dose-response relationship on comparisons of modeled patients treated with older treatment
techniques.4 The doses were only estimated, however, using
a single CT scan of a woman of typical body habitus. Our
study is hypothesis generating and contributes complementary data from a more modern data set in which doses overall are much lower, and individual patient doses can
definitively be identified. Such findings together may be
helpful in identifying patients who may need aggressive
cardiac monitoring owing to a higher risk of a cardiac
event. The current work seeks to build on existing cardiac
dose studies by determining whether imaging or blood biomarkers might further help to identify which patients are at
highest risk in the current era in which radiation doses are
overall considerably lower than in historical studies.
Because the use of MR techniques at 3 time points in this
study was not more effective than an analysis of bloodbased biomarkers, our findings point to the latter as a more
promising possibility of a cost-effective biomarker assessment in this context given the lower cost, broader availability, and greater convenience.
In conclusion, in this left-sided breast cancer cohort, our
data showed no significant correlation between radiation

International Journal of Radiation Oncology  Biology  Physics

dose and either changes on sequential MRI scans or the
majority of serum biomarkers studied. A correlation, however, was identified between mean heart dose and 2 promising possible serum biomarkers that merits further
investigation: IL-6 and troponin I. Future studies should
seek to validate these observations. If these findings are verified in a larger sample, they could have substantial clinical
implications, ranging from refinements in radiation planning and delivery in the treatment of early-stage breast cancer to better targeted supportive care and studies of
potential early pharmacologic intervention.
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